A legacy of impact
Our scientists have created a therapy against the Ebola virus, discovered an early diagnostic for breast cancer and provided data that brought potentially harmful chemicals in personal-care products to light.
As the premier scientific research institute in the nation’s fastest-growing research university, Biodesign’s impact is accelerating. These are just a handful of ways our research is answering today’s challenges.
By 2023, Biodesign’s estimated annual impact on Arizona’s economy will reach $2.9 billion.
Biodesign has attracted over $760 million in funding from grants as well as philanthropic and industry sources.
Scientists at Biodesign are undertaking research in over 200 active research projects.
Clinical Testing Laboratory
When COVID-19 appeared in Arizona, we sprang into action to protect our community. Biodesign’s Clinical Testing Lab created the first saliva-based COVID-19 PCR test publicly available in the U.S. Today, the lab tracks critical COVID-19 trends and partners with the state to provide public testing.
Spotlight: Infectious disease
New study explores role of key protein in regulating infection by salmonella
Infectious diseases continue to ravage human society and remain a leading cause of illness and death worldwide. Improving therapies to treat these afflictions will require a better understanding of the intricate dance between infectious pathogens and the human cells they infect.
ASU Researchers solve a Lyme disease mystery
Researchers from the Biodesign Center for Applied Structural Discovery advance the race for new therapeutics.
ASU teams up with Phoenix Children’s and Valleywise Health to study vaccine effectiveness vs. influenza, COVID-19
Project builds on the ongoing, year-to-year efforts by the Centers for Disease Control and Prevention to evaluate how well influenza vaccines perform across populations and under a range of conditions.